Across TCGA pan-cancer cohorts, C1orf189 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C1orf189 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher C1orf189 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C1orf189 expression acts as an unfavorable survival marker.
THYM and COAD are the cancer types where C1orf189 Mutation most reproducibly stratifies survival.